![](/images/graphics-bg.png)
Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience
المؤلفون المشاركون
Scorsone, Alessandro
Saura, Gabriella
Fleres, Mattia
Spano, Lucia
Aiello, Vito
Brancato, Davide
Di Noto, Anna
Provenzano, Francesca
Provenzano, Vincenzo
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-05-03
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Introduction.
This study aimed at evaluating the efficacy and safety of dapagliflozin in patients with type 2 diabetes (T2D) who also received metformin in clinical practice in Italy.
Methods.
This was a retrospective observational study and it included data from patients who received dapagliflozin 10 mg once daily in conjunction with metformin for 12 months (DAPA + MET).
In those with inadequate glycemic control, insulin or glimepiride was added after 30 days (DAPA + MET + other glucose-lowering drugs).
Efficacy assessments included glycosylated hemoglobin (HbA1c) levels at 6 and 12 months, as well as body mass index (BMI) and lipid parameters at 12 months.
Safety was also assessed.
Results.
Data on 66 patients were included.
In both groups, HbA1c was significantly reduced at 6 and 12 months compared with baseline and significant reductions in HbA1c were observed at 12 months compared with 6 months.
Over the 12-month treatment period, dapagliflozin significantly reduced BMI in both groups.
No significant changes in lipid parameters were observed in either group and no detrimental effects on renal function were detected.
Conclusions.
Dapagliflozin is effective and safe in patients with T2D also receiving metformin.
Glycemic control was already achieved with dapagliflozin + metformin, and add-on therapy was not associated with further improvements.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Scorsone, Alessandro& Saura, Gabriella& Fleres, Mattia& Spano, Lucia& Aiello, Vito& Brancato, Davide…[et al.]. 2018. Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience. Journal of Diabetes Research،Vol. 2018, no. 2018, pp.1-5.
https://search.emarefa.net/detail/BIM-1183971
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Scorsone, Alessandro…[et al.]. Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience. Journal of Diabetes Research No. 2018 (2018), pp.1-5.
https://search.emarefa.net/detail/BIM-1183971
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Scorsone, Alessandro& Saura, Gabriella& Fleres, Mattia& Spano, Lucia& Aiello, Vito& Brancato, Davide…[et al.]. Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience. Journal of Diabetes Research. 2018. Vol. 2018, no. 2018, pp.1-5.
https://search.emarefa.net/detail/BIM-1183971
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1183971
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)